17^th December, 2020 – Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer. The agreement not only opens up new opportunities for development of NK-antibody combination therapies but also has significant positive impact on the production time of Glycostem’s lead product oNKord^® and its second (CAR-NK) and third (TCR-NK) generation therapies – viveNK^TM.